The drug use variables included current injecting (yes or no), frequency of injecting, main type of drug injected, time elapsed since start of injecting drug use, frequency of non-injecting drug use and type of drug used mainly as non-injecting drug.
Therefore, in bivariate analysis, to adjust for variation in time from start of injecting (and thus time of exposure), all other variables were adjusted for time from start of injecting as a time-updated variable.
Using the Kaplan-Meier method, we examined the time elapsed from the start of injecting drugs to HCV seroconversion.
Only HCV-negative DU were included and they were considered to be at risk from their start of injecting.
Time since start injecting can be seen as a proxy for the duration of exposure time, and preliminary analysis showed a very strong association between time since start of injecting and the timepoint of HCV seroconversion (IRR 0.80 per year), 95% CI 0.74, 0.86) (Table 2).
105 operation conditions including variations in start of injection (SOI), injected fuel mass (FMI), and external exhaust gas recirculation (EGR) were selected to assess the model performance.
Testing prior to starting the study indicated there was no appreciable difference between the feel of injecting saline versus NV-01 through a 20G catheter, allowing masking to be complete.
After correction for time since starting injection, the following risk factors were found to be significantly associated with an increased risk of HCV seroconversion: the combined variable of current injecting and current borrowing of needles, earlier calendar year of visit, use of NEP, type of drugs injected, frequency of injecting drug use, and earlier decennium of starting injection (Table 2).
A correlation was found between the amount of injected radioactivity and NGAL levels.
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review.
